Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
BMJ Open. 2021 Sep 15;11(9):e047475. doi: 10.1136/bmjopen-2020-047475.
The health-related quality of life (HRQoL) and utilities of patients with chronic hepatitis B (CHB) virus infection, including compensated cirrhosis (CC), decompensated cirrhosis (DC) and different stages of hepatocellular carcinoma (HCC), have not been well described in China. This study aimed to evaluate HRQoL and utilities and provide parameters for the economic evaluation of CHB-related diseases.
We conducted a multicentre cross-sectional and study to measure the HRQoL of patients with CHB, CC, DC and HCC using the Chinese short form (SF) 36 health survey V.2. The utilities were extracted based on the SF-six dimension scoring model. Multivariable regression analyses identified the effects on HRQoL.
A total of 1071 patients (639 with CHB, 125 with CC, 85 with DC and 222 with HCC) were invited to complete the questionnaire. Physical HRQoL was not impaired in the CHB stage, while mental HRQoL was significantly impaired. Physical composite summary scores have a more significant decrease than mental composite summary scores at the advanced stages (CC, DC and HCC). The utility scores of CHB only, CC, DC and HCC were 0.773, 0.750, 0.683 and 0.640, respectively. The utility scores in the early, middle and terminal stages of HCC were 0.656, 0.635 and 0.615, respectively.
Slowing the progress of CHB-related diseases and providing psychological support early are the key points to improving the quality of life with the diseases. The utility values estimated in this study can provide a vital instrument for cost-effectiveness studies on CHB-related diseases.
在中国，慢性乙型肝炎（CHB）病毒感染者的健康相关生活质量（HRQoL）和效用尚未得到很好的描述，包括代偿性肝硬化（CC）、失代偿性肝硬化（DC）和不同阶段的肝细胞癌（HCC）。本研究旨在评估 CHB 相关疾病的 HRQoL 和效用，并提供经济评估参数。
我们进行了一项多中心横断面研究，使用中国短式（SF）36 健康调查 V.2 测量 CHB、CC、DC 和 HCC 患者的 HRQoL。效用根据 SF-六维评分模型提取。多变量回归分析确定了对 HRQoL 的影响。
共邀请 1071 名患者（639 名 CHB、125 名 CC、85 名 DC 和 222 名 HCC）完成问卷。CHB 阶段的身体 HRQoL 未受损，而心理 HRQoL 显著受损。在晚期（CC、DC 和 HCC），身体综合评分较心理综合评分下降更为明显。CHB 仅、CC、DC 和 HCC 的效用评分分别为 0.773、0.750、0.683 和 0.640。HCC 的早期、中期和晚期的效用评分分别为 0.656、0.635 和 0.615。
减缓 CHB 相关疾病的进展并尽早提供心理支持是提高疾病生活质量的关键。本研究中估计的效用值可为 CHB 相关疾病的成本效益研究提供重要工具。
